Author: Moody, M. Anthony
Title: Modulation of HIV-1 immunity by adjuvants Cord-id: 1nm1tbig Document date: 2014_4_10
ID: 1nm1tbig
Snippet: PURPOSE OF REVIEW: To summarize the role of adjuvants in eliciting desirable antibody responses against HIV-1 with particular emphasis on both historical context and recent developments. RECENT FINDINGS: Increased understanding of the role of pattern recognition receptors such as Toll-like receptors in recruiting and directing the immune system has increased the variety of adjuvant formulations being tested in animal models and humans. Across all vaccine platforms, adjuvant formulations have bee
Document: PURPOSE OF REVIEW: To summarize the role of adjuvants in eliciting desirable antibody responses against HIV-1 with particular emphasis on both historical context and recent developments. RECENT FINDINGS: Increased understanding of the role of pattern recognition receptors such as Toll-like receptors in recruiting and directing the immune system has increased the variety of adjuvant formulations being tested in animal models and humans. Across all vaccine platforms, adjuvant formulations have been shown to enhance desirable immune responses such as higher antibody titers and increased functional activity. Although no vaccine formulation has yet succeeded in eliciting broad neutralizing antibodies against HIV-1, the ability of adjuvants to direct the immune response to immunogens suggests they will be critically important in any successful HIV-1 vaccine. SUMMARY: The parallel development of adjuvants along with better HIV-1 immunogens will be needed for a successful AIDS vaccine. Additional comparative testing will be required to determine the optimal adjuvant and immunogen regimen that can elicit antibody responses capable of blocking HIV-1 transmission.
Search related documents:
Co phrase search for related documents- acceptable risk and adjuvant development: 1
- acceptable risk and adjuvant development face: 1
- acceptable risk and adjuvant immunogen: 1
- acceptable risk and adjuvant inferior: 1
- acceptable risk and adjuvant superior: 1
- acceptable risk and adjuvant vaccine: 1
- acceptable risk and adjuvant vaccine inferior: 1
- acceptable risk level and adjuvant development: 1
- acceptable risk level and adjuvant development face: 1
- acceptable risk level and adjuvant immunogen: 1
- acceptable risk level and adjuvant inferior: 1
- acceptable risk level and adjuvant superior: 1
- acceptable risk level and adjuvant vaccine: 1
- acceptable risk level and adjuvant vaccine inferior: 1
- acceptable risk public judgment and adjuvant development: 1
- acceptable risk public judgment and adjuvant development face: 1
- acceptable risk public judgment and adjuvant immunogen: 1
- acceptable risk public judgment and adjuvant inferior: 1
Co phrase search for related documents, hyperlinks ordered by date